echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Urinary System > Express first-line treatment of advanced bladder cancer, blockbuster PD-1 inhibitor was fully approved by the US FDA

    Express first-line treatment of advanced bladder cancer, blockbuster PD-1 inhibitor was fully approved by the US FDA

    • Last Update: 2021-10-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    ▎MSD, editor of WuXi AppTec's content team, announced today that the US FDA has approved the label update of the anti-PD-1 therapy Keytruda for the first-line treatment of advanced urothelial cancer (bladder cancer)
    .

    The US FDA has converted this indication from accelerated approval to full approval
    .

    In addition, the indication was revised to be used for the treatment of locally advanced or metastatic urothelial carcinoma (mUC) patients who are not suitable for any platinum-containing chemotherapy regimens
    .

    Previously, Keytruda is indicated for the treatment of locally advanced or mUC patients who are not suitable for cisplatin-containing chemotherapy and whose tumors express PD-L1 ([CPS]≥10), or are not suitable for any platinum-containing chemotherapy (regardless of PD-L1 status) Of patients
    .

    Based on the tumor remission rate and duration of remission, this indication has been granted accelerated approval
    .

    The subsequent phase 3 trial KEYNOTE-361 evaluated the effect of Keytruda as a single-agent therapy in combination with chemotherapy in the first-line treatment of patients with advanced or mUC who are suitable for platinum-containing chemotherapy
    .

    Compared with standard chemotherapy, Keytruda did not meet the pre-specified dual primary endpoint of overall survival or progression-free survival
    .

    The label update follows the U.
    S.
    FDA Oncology Drug Advisory Committee (ODAC) meeting held earlier this year as part of an accelerated approval evaluation for industry-wide failure to meet post-marketing requirements
    .

    Members voted (5-3) in favor of maintaining the accelerated approval of Keytruda's first-line bladder indication
    .

    Dr.
    Scot Ebbinghaus, Vice President of Clinical Research at Merck Laboratories, said: “While the treatment landscape is constantly changing, certain newly diagnosed patients with advanced urothelial cancer who are not suitable for platinum-containing chemotherapy still have unmet needs
    .

    We continue to Keytruda We are confident in the role played by these patients, who have few other treatment options, and are working hard to advance research to help more patients with bladder cancer and other types of cancer
    .

    "Reference: [1] FDA Approves Updated Indication for Merck's KEYTRUDA ® (pembrolizumab) for Treatment of Certain Patients With Urothelial Carcinoma (Bladder Cancer).
    Retrieved August 31, 2021, from https:// Note: This article aims to introduce medical health research Progress is not a recommended treatment plan
    .

    If you need guidance on the treatment plan, please go to a regular hospital for treatment
    .

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.